Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2010

Phylogica Taps Isogenica’s In Vitro Display Technology

  • Australian-based biopharmaceutical company Phylogica will use Isogenica’s CIS display technology to optimize the performance of three of its lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

    CIS display, an in vitro display technology, allows the generation of polypeptide libraries of unprecedented size and complexity, according to Isogenica. It is then possible to select polypeptides with high affinity and specificity for most targets, the company continues.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »